The Cancer Letter

Inside information on cancer research and drug development

Clinical

Kura Oncology announces positive phase II study for Tipifarnib in HRAS mutant disease

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
BYLINE
IN THIS ISSUE
DOWNLOAD PDFTABLE OF CONTENTS

Kura Oncology announced positive topline results from a phase II trial for tipifarnib in patients with HRAS mutant relapsed or refractory squamous cell carcinomas of the head and neck. The phase II trial achieved its primary endpoint prior to the completion of enrollment.

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Clinical Roundup

Proton therapy demonstrates advantages for head and neck cancer in phase III trial preliminary data

According to preliminary data from a multi-institution phase III trial led by researchers at MD Anderson Cancer Center, intensity modulated proton therapy achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy as part of chemoradiation treatment for patients with oropharyngeal cancer. 
Table of Contents

Login

Site license subscribers:
Log in with your IP | Register a sponsored account